简介：AIM:Toevaluatetheefficacyofthe14-dmoxifloxacinbasedtripletherapyforthesecond-lineeradicationofHelicobacterpylori(H.pylori)infection.METHODS:Between2011and2013,weconductedaretrospectivereviewofthemedicalrecordsof160patientswhohadexperiencedfailureoftheirfirst-lineprotonpumpinhibitor-basederadicationtherapyandsubsequentlyreceivedthemoxifloxacin-basedtripletherapyasasecond-lineeradicationtreatmentregimen.Thepatientswhoweretreatedwiththemoxifloxacinbasedtripletherapy(oral20mgrabeprazoleb.i.d.,1000mgamoxicillinb.i.d.,and400mgmoxifloxacinq.d.)for7dwereassignedtotheRAM-7group(n=79)whilethosewhotookthemfor14dayswereassignedtoRAM-14group(n=81).Theeradicationratesforbothgroupsweredeterminedbyintentionto-treat(ITT)andper-protocol(PP)analyses.ITTanalysiscomparedthetreatmentgroupsasoriginallyallocatedwhilethePPanalysisincludingonlythosepatientswhohadcompletedthetreatmentasoriginallyallocated.SuccessfuleradicationtherapyforH.pyloriinfectionwasdefinedasthedocumentationofanegative13C-ureabreathtest4wkaftertheendoftheeradicationtreatment.RESULTS:TheoverallITTeradicationratewas76.2%(122/160).ThefinalITTeradicationrateswere70.8%(56/79;95%CI:63.3%-77.1%)intheRAM-7groupand81.4%(66/81;95%CI:74.6%-88.3%)intheRAM-14group(P=0.034).TheoverallPPeradicationratewas84.1%(122/145),andthefinalPPeradicationrateswere77.7%(56/72;95%CI:70.2%-85.3%)intheRAM-7groupand90.4%(66/73;95%CI:82.8%-98.1%)intheRAM-14group(P=0.017).TheH.pylori-eradicationratesintheRAM-14groupweresignificantlyhighercomparedwiththatoftheRAM-7groupaccordingtoboththeITT(P=0.034)andthePPanalyses(P=0.017).Bothgroupsexhibitedgoodtreatmentcompliance(RAM-7/RAM-14group:100%/100%).Theadverseeventrateswere19.4%(14/72)and20.5%(15/73)intheRAM-7andRAM-14groups,respectively(P=0.441).Adverseeventsoccurredin14

简介：AIM:Toinvestigatetheefficacyofneoadjuvantchemoradiotherapy(NACRT)forresectabilityoflocallyadvancedgastriccancer(LAGC).METHODS:BetweenNovember2007andJanuary2014,29patientswithLAGC(clinicallyT3withdistalesophagusinvasion/T4orbulkyregionalnodemetastasis)thatweretreatedwithNACRTfollowedbyD2gastrectomywereincludedinthisstudy.ResectabilitywasevaluatedwithradiologicandendoscopicexamsbeforeandafterNACRT.Usingthreedimensionalconformalradiotherapy,patientsreceived45Gy,withadailydoseof1.8Gy.Theentiretumorextentandtheregionalmetastaticlymphnodeswereincludedinthegrosstumorvolume.PatientspresentingwitharesectabletumorafterNACRTreceivedatotalorsubtotalgastrectomywithD2dissection.ThepathologictumorresponsewasevaluatedusingJapaneseGastricCancerAssociationhistologicevaluationcriteria.PostoperativemorbiditywasevaluatedusingtheNationalCancerInstitute-CommonTerminologyCriteriaforAdverseEventsversion4.0.Overallsurvival(OS)andprogression-freesurvival(PFS)rateswereestimatedusingaKaplan-Meieranalysisandcomparedusingthelog-ranktest.RESULTS:Allpatientswereassessedasunresectablecases.Twenty-fourpatients(24/29;82.8%)showedLAGConpositronemissiontomography-computedtomography(CT)andcontrast-enhancedCT,whereasfourpatients(4/29;13.8%)withvagueinvasionorabutmenttoanadjacentorganunderwentdiagnosticlaparoscopy.Onepatient(1/29;3.4%),initiallyassessedasaresectablecase,underwentan'openandclosure'afterthetumorwasfoundtobeunresectable.Abutmenttoanadjacentorgan(34.5%)wasthemostcommonreasonforNACRT.TheclinicalresponserateonemonthafterNACRTwas44.8%.AfterNACRT,69%(20/29)ofpatientshadaresectabletumor.Ofthe20patientswitharesectabletumor,18patients(62.1%)underwentaD2gastrectomy.TheR0resectionratewas94.4%andtwopatients(2/18;11.1%)showedacompleteresponse.Themedianfollow-updurationwas13.5mo.Theone-yearOSandPFS

简介：背景：维生素D受体（VDR）属于类固醇激素受体超家族，参与细胞增殖、分化、凋亡以及免疫应答等多种生物学过程，在多种恶性肿瘤中呈低表达。目的：探讨VDR在结直肠癌中的表达及其调控机制。方法：收集2010年2月-2012年12月上海交通大学医学院附属仁济医院收治的结直肠癌患者30例，以免疫组化法检测癌组织和相应癌旁非癌组织标本的VDR表达情况。从基因表达汇编（GEO）数据库中提取224例结直肠癌患者的临床资料，分析其癌组织VDR表达与患者临床病理特征和生存期的关系。采用组蛋白-赖氨酸N-甲基转移酶EZH2-siRNA或5-氮杂胞嘧啶核苷（5-AZA）处理人结肠癌细胞株HCT116和SW620，以实时PCR检测VDR表达水平，以甲基化特异性PCR（MSP）检测VDR启动子区甲基化水平。结果：结直肠癌患者癌组织VDR阳性表达率显著低于癌旁非癌组织（26.7%对70.0%，P〈0.001）。结直肠癌组织VDR表达与肿瘤组织学分期、远处转移、脉管转移、淋巴结转移呈负相关（P〈0.05）；VDR高表达者生存期显著长于低表达者（P=0.032）。与转染对照-siRNA相比，HCT116、SW620细胞转染EZH2-siRNA后，EZH2mRNA表达水平和VDR启动子区甲基化水平均显著降低（P〈0.05），VDRmRNA表达水平显著升高（P〈0.05）。5-AZA处理HCT116、SW620细胞后，VDR启动子区甲基化水平较阴性对照组显著降低（P〈0.05），VDRmRNA表达水平显著升高（P〈0.05）。结论：结直肠癌中VDR表达下调且与患者预后呈正相关。VDR在结直肠癌中的转录抑制受组蛋白甲基化和DNA甲基化共同调控。

简介：目的探讨补气健脾祛湿方联合艾迪沙、培菲康治疗溃疡性结肠炎的临床疗效及对血清SOD、MDA和炎性因子水平的影响。方法选择2012年1月至2013年7月消化内科收治的110例溃疡性结肠炎患者纳入研究并按照其就诊顺序随机分为两组,各55例,对照组口服艾迪沙、培菲康胶囊治疗,而观察组在此基础上联合应用补气健脾祛湿方,比较两组治疗效果及血清SOD、MDA和炎性因子的差异。结果观察组总有效率显著高于对照组,而复发率显著低于对照组,且两组间差异具有统计学意义（P〈0.05）;两组治疗前TNF-α、CRP和IL-6水平无显著性差异（P〉0.05）;而两组治疗后各指标均较治疗前显著降低,且两组间差异有统计学意（P〈0.05）;观察组治疗后SOD活力显著升高而MDA水平显著降低（P〈0.05）。结论补气健脾祛湿方联合艾迪沙、培菲康治疗消化性溃疡的临床疗效明显优于单用西药治疗,适合临床推广和应用。